SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats.
In rats injected with the toxin monocrotaline, altered synthesis and distribution of pulmonary artery elastin suggest that increased elastase activity may be important in the development of vascular changes and progressive pulmonary hypertension. To test this hypothesis, male Sprague-Dawley rats (250-300 g) were given 40 mg/kg of the elastase inhibitor SC-39026 in a carboxymethylcellulose vehicle or vehicle only by gavage, 12 hours before and twice daily for 8 days after a single subcutaneous injection of either monocrotaline (60 mg/kg) or saline. Thirteen days after injection, indwelling cardiovascular catheters were inserted under pentobarbital anesthesia, and at 15 days after injection, pulmonary and systemic hemodynamic measurements were recorded with the animals awake. At post-mortem examination, the lungs were perfused and morphometric techniques applied for light and electron microscopic evaluation. Saline-injected rats given either SC-39026 or vehicle were similar in all features assessed. In contrast, monocrotaline-injected rats given SC-39026 had significantly lower mean pulmonary artery pressure than those given vehicle (21.0 +/- 1.6 vs. 27.5 +/- 0.8 mm Hg, p less than 0.05), and this correlated with a significant reduction in the number of abnormally muscularized arteries at alveolar wall level (r2 = 0.89, p less than 0.001). SC-39026 did not significantly reduce monocrotaline-induced medial hypertrophy of muscular arteries, endothelial injury, and associated subendothelial edema; nor was there a significant increase in the proportion of the medial elastin, although a trend was apparent. Additional groups of monocrotaline injected rats were followed 3 weeks after injection, but both SC-39026 and vehicle-treated rats were similar at this point. Our data suggest that increased serine elastase activity associated with endothelial injury may mediate early abnormal pulmonary vascular smooth muscle differentiation resulting in muscularization of normally nonmuscular peripheral arteries and pulmonary hypertension induced in rats by injection of the toxin monocrotaline. Lack of persistence of this protective effect suggests that there may be continued elastase activity in this model. Failure to inhibit medial hypertrophy with SC-39026 suggests that a different mechanism or a different elastase may be involved in this structural change.
Ilkiw
R
R
Department of Cardiology and Pathology, Hospital for Sick Children, Toronto, Ontario, Canada.
Todorovich-Hunter
L
L
Maruyama
K
K
Shin
J
J
Rabinovitch
M
M
D000818:Animals; D001158:Arteries / Q000473:pathology*; D002723:Chlorobenzoates / Q000494:pharmacology*; D006439:Hemodynamics; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology*; D008168:Lung / Q000098:blood supply*; D008297:Male; D016686:Monocrotaline; D010196:Pancreatic Elastase / Q000378:metabolism; D011651:Pulmonary Artery / Q000473:pathology; D011763:Pyrrolizidine Alkaloids; D051381:Rats
D002723:Chlorobenzoates; D011763:Pyrrolizidine Alkaloids; C053557:lodelaben; D016686:Monocrotaline; D010196:Pancreatic Elastase